KemPharm Inc. (KMPH) Stock Rating Lowered by Zacks Investment Research
KemPharm Inc. (NASDAQ:KMPH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday.
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
Separately, Canaccord Genuity reissued a “buy” rating on shares of KemPharm in a report on Wednesday, August 10th.
KemPharm (NASDAQ:KMPH) opened at 4.10 on Tuesday. The company has a 50-day moving average price of $4.08 and a 200 day moving average price of $5.08. KemPharm has a 12 month low of $3.20 and a 12 month high of $20.60. The company’s market capitalization is $60.05 million.
In other news, EVP Daniel L. Cohen acquired 10,000 shares of the firm’s stock in a transaction on Tuesday, September 6th. The shares were purchased at an average cost of $4.75 per share, with a total value of $47,500.00. Following the acquisition, the executive vice president now directly owns 1,310 shares in the company, valued at approximately $6,222.50. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 22.80% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Kennedy Capital Management Inc. raised its position in shares of KemPharm by 10.4% in the first quarter. Kennedy Capital Management Inc. now owns 55,126 shares of the specialty pharmaceutical company’s stock worth $799,000 after buying an additional 5,211 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of KemPharm by 37.2% in the first quarter. Goldman Sachs Group Inc. now owns 85,753 shares of the specialty pharmaceutical company’s stock worth $1,243,000 after buying an additional 23,244 shares in the last quarter. William Harris Investors Inc. raised its position in shares of KemPharm by 93.3% in the second quarter. William Harris Investors Inc. now owns 30,891 shares of the specialty pharmaceutical company’s stock worth $123,000 after buying an additional 14,911 shares in the last quarter. Parkwood LLC purchased a new position in shares of KemPharm during the second quarter worth approximately $107,000. Finally, Arete Wealth Advisors LLC raised its position in shares of KemPharm by 0.8% in the third quarter. Arete Wealth Advisors LLC now owns 834,602 shares of the specialty pharmaceutical company’s stock worth $3,747,000 after buying an additional 6,857 shares in the last quarter. 46.33% of the stock is currently owned by hedge funds and other institutional investors.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.